GALMED PHARMACEUTICALS LTD. Deferred Tax Assets, Capital Loss Carryforwards
GALMED PHARMACEUTICALS LTD. (GLMD) had Deferred Tax Assets, Capital Loss Carryforwards of $205.90 million as of 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Capital Loss Carryforwards $205.90M.
- 2024-12-31: Deferred Tax Assets, Capital Loss Carryforwards $175.40M.
- 2023-12-31: Deferred Tax Assets, Capital Loss Carryforwards $165.10M.
- 2022-12-31: Deferred Tax Assets, Capital Loss Carryforwards $152.00M.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2025-12-31 | $205.90M 20-F · filed 2026-03-31 |
| 2024-12-31 | $175.40M 20-F · filed 2025-04-02 |
| 2023-12-31 | $165.10M 20-F · filed 2024-04-04 |
| 2022-12-31 | $152.00M 20-F · filed 2023-03-29 |
| 2021-12-31 | $126.00M 20-F · filed 2022-05-02 |
| 2020-12-31 | $2.40M 20-F · filed 2021-03-18 |
| 2019-12-31 | $3.50M 20-F · filed 2020-03-12 |
| 2018-12-31 | $1.20M 20-F · filed 2019-03-13 |
| 2017-12-31 | $570.00K 20-F · filed 2018-03-13 |
| 2016-12-31 | $407.00K 20-F · filed 2017-03-23 |